DexCom's CONNECT Study Published In The New England Journal Of Medicine; Findings Support The Role Of CGM Earlier In Type 2 Diabetes Care For All People, Including Those Over The Age Of 65

Benzinga · 1d ago
  • Publication marks the first time in nearly two decades that The New England Journal of Medicine has published clinical data on standalone real-time continuous glucose monitoring (CGM) technology, dating back to the creation of the CGM category.
  • Randomized controlled trial demonstrates Dexcom G7 significantly reduces A1C and improves glucose control compared with routine care.
  • Benefits observed across a broad range of participants, including those taking GLP-1 medications.1
  • Findings support the role of CGM earlier in Type 2 diabetes care for all people, including those over the age of 65.

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced that results from the landmark CONNECT randomized controlled trial have been published in The New England Journal of Medicine (NEJM), providing rigorous evidence of the significant benefits of continuous glucose monitoring (CGM) for adults with Type 2 diabetes not on insulin.